| Source | Evidence on protein | Close homologs |
|---|---|---|
| Cuervo et al. | no | yes: 0 |
| Hassani et al. | no | yes: 0 |
| Forrest at al. (metacyclic) | no | yes: 0 |
| Forrest at al. (procyclic) | no | yes: 0 |
| Silverman et al. | no | yes: 0 |
| Pissara et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Pires et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Silverman et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Jamdhade et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| DeepLoc | ||
| SignalP6 | no | yes: 0, no: 4 |
| NetGPI | no | yes: 0, no: 4 |
| Term | Name | Level | Count |
|---|---|---|---|
| GO:0016020 | membrane | 2 | 4 |
| GO:0110165 | cellular anatomical entity | 1 | 4 |
Related structures:
AlphaFold database: Q4QD75
| Leishmania | From | To | Domain/Motif | Score |
|---|---|---|---|---|
| CLV_PCSK_SKI1_1 | 6 | 10 | PF00082 | 0.402 |
| DEG_APCC_DBOX_1 | 3 | 11 | PF00400 | 0.594 |
| DOC_CYCLIN_yCln2_LP_2 | 59 | 65 | PF00134 | 0.394 |
| DOC_MAPK_MEF2A_6 | 48 | 57 | PF00069 | 0.491 |
| DOC_PP1_RVXF_1 | 4 | 10 | PF00149 | 0.469 |
| LIG_FHA_2 | 32 | 38 | PF00498 | 0.418 |
| LIG_Pex14_2 | 64 | 68 | PF04695 | 0.456 |
| LIG_SH2_PTP2 | 76 | 79 | PF00017 | 0.471 |
| LIG_SH2_SRC | 76 | 79 | PF00017 | 0.394 |
| LIG_SH2_STAP1 | 23 | 27 | PF00017 | 0.296 |
| LIG_SH2_STAT5 | 76 | 79 | PF00017 | 0.471 |
| LIG_TRAF2_1 | 39 | 42 | PF00917 | 0.570 |
| LIG_TYR_ITIM | 74 | 79 | PF00017 | 0.394 |
| MOD_GSK3_1 | 80 | 87 | PF00069 | 0.442 |
| MOD_Plk_4 | 23 | 29 | PF00069 | 0.394 |
| MOD_Plk_4 | 81 | 87 | PF00069 | 0.604 |
| TRG_DiLeu_BaLyEn_6 | 3 | 8 | PF01217 | 0.638 |
| TRG_ENDOCYTIC_2 | 76 | 79 | PF00928 | 0.471 |
| TRG_ER_diArg_1 | 4 | 7 | PF00400 | 0.708 |
| Protein | Taxonomy | Sequence identity | Coverage |
|---|---|---|---|
| A0A3S5H771 | Leishmania donovani | 89% | 100% |
| A4HA85 | Leishmania braziliensis | 62% | 100% |
| A4HYG6 | Leishmania infantum | 89% | 100% |